Список проголосовавших за комментарий " <table class="BriefingDataTable" border="0" cellspacing="0" cellpadding="0"><tr> <td class="tickerColumn"> </td> <td class="articleColumn">Quidel target raised earlier to $24.50 at Canaccord Genuity following earnings (24.79 +1.29)Canaccord Genuity raises their QDEL tgt to $24.50 from $24 noting, «We maintain our Hold given that <strong>we believe the next wave of growth is likely to inflect next Dec. or Jan. when the next flu season rolls in.</strong> That said, QDEL expects FDA approvals of Lyme disease and Vitamin D initially on Sofia 1 later this year with some contribution in 2H/17, though we believe the more meaningful inflection will take place on Sofia 2 (2018 likely) where the company looks to secure CLIA-waivers. Given this, we believe the bigger inflection comes in '18.»</td> </tr></table>"